header photo


The original monobenzone cream



Actions & Uses

  • Benoquin cream exerts a powerful inhibiting effect on pigment formation in the melanin-producing cells of the skin.
  • Benoquin cream can be used for patients with ‘generalised vitiligo’ who wish to achieve a uniform white color on the body.
  • Benoquin cream cannot be used to treat hyperpigmentation resulting from pigments other than melanin. These include bile, silver or artificial pigments incorporated into the skin. 
  • Benoquin has not proven in the treatment of café au lait spots or in malignant melanoma.


  • Benoquin cream is to be rubbed on the desired areas two or three times daily until the desired degree of depigmentation is obtained.
  • Exposing the treated areas to sunlight should be avoided since ultraviolet radiant tends to neutralize the depigmentation of the drug.
  • Depigmentation is usually observed after one to four months of daily application generally after the first month.
  • At times a burning sensation for five to twenty minutes duration may be experienced shortly after the application of the cream. The burning sensation will, as a rule, disappear after several weeks of use and does not require discontinuation of therapy.
  • After the desired pigmentation is obtained, apply the cream only as necessary to maintain the results. Treatment may be as infrequent as two applications per week.

Mechanism of action

  • Monobenzone is a depigmenting agent whose mechanism of action is not fully understood. The topical application of monobenzone in animals increases the excretion of melanin from the melanocytes. The same action is thought to be responsible for the depigmenting effect of the drug in humans. 
  • Monobenzone may cause destruction of melanocytes and permanent depigmentation. This effect is variable and may take one to four months to occur while existing melanin is lost with normal sloughing of the stratum corneum.
  • Hyperpigmented skin appears to fade more rapidly than normal skin, and exposure to sunlight reduces the depigmenting effect of the drug.
  • The histology of the skin after depigmentation with topical monobenzone is the same as that seen in vitiligo; the epidermis is normal except for the absence of identifiable melanocytes.


Before using Benoquin, tell your doctor if you are allergic to monobenzone or to hydroquinone; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Discuss with your doctor for more details. Before using this medication, tell your doctor of your medical history, especially of other skin conditions. During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor. It is not known whether this drug passes into breast milk. Consult your doctor before breast-feeding.


*DiscalimerThis information is for educational purpose only. Please consult a physician before using Benoquin.